GC PRIDE INJECTION

Levosulpiride 12.5 mg Injection

 

Levosulpiride

It is a substituted benzamide antipsychotic which is reported to be a selective antagonist of central dopamine (D-2, D-3 & D-4) receptors, also have mood elevating properties.

INDICATIONS OF LEVOSULPIRIDE 12.5MG:

• ANXIETY,
• DEPRESSION,
• PSYCHOSES SUCH AS SCHIZOPHRENIA,
• VERTIGO
•  PEPTIC ULCERATIONS.

SIDE EFFECTS OF LEVOSULPIRIDE 12.5MG:

• AMENORRHOEA,
• GYNAECOMASTIA,
• GALACTORRHOEA,
• CHANGES IN LIBIDO.
• POTENTIALLY FATAL:
• NEUROLEPTIC MALIGNANT SYNDROME.

DRUG INTERACTIONS OF LEVOSULPIRIDE 12.5MG:

REDUCED BIOAVAILABILITY WITH SUCRALFATE, ALUMINIUM- AND MAGNESIUM-CONTAINING ANTACIDS. EFFECT ON GI MOTILITY MAY BE ANTAGONISED BY ANTICHOLINERGIC AGENTS, NARCOTICS AND ANALGESICS. AVOID ALCOHOL.

CONTRAINDICATIONS OF LEVOSULPIRIDE 12.5MG:

• PHAEOCHROMOCYTOMA,
• EPILEPSY,
• MANIC STATES,
• HYPERPROLACTINAEMIA,
• MAMMARY DYSPLASIA,
• MALIGNANT MASTOPATHIES,
• CARDIAC IMPAIRMENT.
• GI BLEEDING,
• MECHANICAL OBSTRUCTION OR PERFORATION.

MECHANISM OF ACTION OF LEVOSULPIRIDE 12.5MG:

LEVOSULPIRIDE IS A SUBSTITUTED BENZAMIDE, WHICH EXERTS ANTIDOPAMINERGIC (SELECTIVE DOPAMINE D2 RECEPTORS) ACTIVITY ON BOTH CENTRAL AND PERIPHERAL LEVELS. IT IS AN ATYPICAL NEUROLEPTIC AND A PROKINETIC AGENT. ABSORPTION: ORAL BIOAVAILABILITY IS ABOUT 30%; PEAK PLASMA CONCENTRATIONS AFTER ABOUT 3 HR. EXCRETION: MAINLY VIA URINE. PLASMA HALF-LIFE: 9.7 HR (ORAL); 4.3 HR (IV).

SPECIAL PRECAUTIONS FOR LEVOSULPIRIDE 12.5MG:

MAY IMPAIR ABILITY TO DRIVE OR OPERATE MACHINERY. PREGNANCY AND LACTATION.

PATIENTS RECEIVING ANTIHYPERTENSIVE, HYPNOTIC & ANALGESIC DRUGS, BECAUSE CONCURRENT USE MAY INCREASE THE EFFECTS OF THESE DRUG.

 

For Use of Registered Medical Practitioner or a Hospital Only.